4SCAR19 and 4SCAR22
Preclinical
4SCAR19 and 4SCAR22 is one of 2 therapeutic programs targeting B-cell Malignancies. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
12 competitors in B-Cell Malignancies
#DrugCompanyPhaseTrials
1Parsaclisib
IncytePhase 2
4SCAR19 and 4SCAR22
SShenzhen Geno-Immune Medical Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 4SCAR19 and 4SCAR22. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]